Over the last two decades virus‑like particles (VLPs) have become an important tool in
biomedical research and medicine. VLPs are multi‑protein structures that resemble viable …

The development of virus-like particle (VLP) technology has had an enormous impact on
modern vaccinology. In order to optimize the efficacy and safety of VLP-based vaccines …

Viruses that infect eukaryotic organisms have the unique characteristic of self-assembling
into particles. The mammalian immune system is highly attuned to recognizing and attacking …

Virus-like particles (VLPs) structurally mimic the viral capsid and have therefore been
extensively, and quite successfully, used as vaccine and viral serology reagents. The ability …

Human vaccines against three viruses use recombinant virus-like particles (VLPs) as the
antigen: hepatitis B virus, human papillomavirus, and hepatitis E virus. VLPs are excellent …

Virus-like particles (VLPs) are of interest in vaccination, gene therapy and drug delivery, but
their potential has yet to be fully realized. This is because existing laboratory processes …

Current vaccines that provide protection against infectious diseases have primarily relied on
attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid …

In recent decades, the development of plant virology and genetic engineering techniques
has resulted in the construction of plant virus-based vaccines for protection against different …

Traditional successful antiviral vaccines have relied mostly on live‐attenuated viruses. Live‐
attenuated HIV vaccine candidates are not ideal as they pose risks of reversion …

The paper discusses the techniques which are currently implemented for vaccine production
based on virus-like particles (VLPs). The factors which determine the characteristics of VLP …